# US 2014/0193433 A1 · Bcma-based stratification and therapy for multiple myeloma patients > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193433 A1 - Document ID: US20140193433A1 - Status: Published application - Kind: A1 - Application number: 14/150,127 - Filed: 2014-01-08 - Published: 2014-07-10 - Earliest claimed: 2011-04-21 - Assignees: Boehringer Ingelheim International GmbH - Inventors: Eric BORGES; Jasmin Barbara HEBEIS - Web page: https://patentgrep.com/patent/US20140193433A1 ## CPC - G01N 33/57505: of the blood, e.g. leukaemia - A61P 7/00: Drugs for disorders of the blood or the extracellular fluid - A61P 35/00: Antineoplastic agents - C07K 16/2803: {against the immunoglobulin superfamily} - C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95} - C07K 16/2887: {against CD20} - C07K 16/3061: {Blood cells} - G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors} - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA is expressed on the cell surface of B-cells, preferably malignant B-cells of a patient. Furthermore, antibody-based therapies for patients who have BCMA positive malignant B-cells are provided. ## Claims ### Claim 1 A method for the stratification of a multiple myeloma (MM) patient disposed to respond favorably to an anti-BCMA antibody therapy, comprising determining whether B-cells, preferably malignant B-cells of said patient express BCMA protein on the surface of said B-cells, wherein said patient is disposed to respond favorably to said anti-BCMA antibody therapy, if said B-cells express BCMA protein on their surface. ### Claim 2 A method for diagnosing a BCMA negative multiple myeloma (MM) patient, comprising determining whether B-cells, preferably malignant B-cells of said patient, express BCMA protein on their surface, wherein said patient suffers from BCMA negative MM, if no BCMA protein is detectable on the surface of said B-cells. ### Claim 3 A method for selecting an antibody-based multiple myeloma (MM) therapy, comprising determining whether B-cells, preferably malignant B-cells of a patient, express BCMA protein on the surface of said B-cells, wherein, if said B-cells are BCMA positive, the patient may be subject to an anti-CD20 antibody therapy and/or an anti-CD38 antibody therapy and/or an anti-BCMA antibody therapy and/or anti-CS1 antibody therapy, or, if said B-cells are BCMA-negative, the patient is subject to an anti-CD20 antibody therapy and/or an anti-CD38 antibody therapy and/or anti-CS1 antibody therapy. ### Claim 4 (depends on 1) The method of claim 1, wherein said B-cells are malignant B-cells of said patient. ### Claim 5 (depends on 2) The method of claim 2, wherein said B-cells are malignant B-cells of said patient. ### Claim 6 (depends on 3) The method of claim 3, wherein said B-cells are malignant B-cells of said patient. ### Claim 7 (depends on 1) The method of claim 1, wherein said B-cells are characterized to be CD38 positive, CD56 positive or negative, CD45 positive, and CD19 positive. ### Claim 8 (depends on 2) The method of claim 2, wherein said B-cells are characterized to be CD38 positive, CD56 positive or negative, CD45 positive, and CD19 positive. ### Claim 9 (depends on 3) The method of claim 3, wherein said B-cells are characterized to be CD38 positive, CD56 positive or negative, CD45 positive, and CD19 positive. ### Claim 10 (depends on 1) The method of claim 1, wherein said patient is to be treated with an anti-BCMA antibody therapy. ### Claim 11 (depends on 2) The method of claim 2, wherein said patient is to be treated with an anti-BCMA antibody therapy. ### Claim 12 (depends on 10) The method of claim 10, wherein said anti-BCMA antibody is a monoclonal antibody, a chimeric antibody a humanized antibody, or a bispecific antibody. ### Claim 13 (depends on 11) The method of claim 11, wherein said anti-BCMA antibody is a monoclonal antibody, a chimeric antibody a humanized antibody, or a bispecific antibody. ### Claim 14 (depends on 10) The method of claim 10, wherein said anti-BCMA antibody is conjugated to a toxin. ### Claim 15 (depends on 11) The method of claim 11, wherein said anti-BCMA antibody is conjugated to a toxin. ### Claim 16 A method for the treatment or amelioration of a multiple myeloma (MM) patient whose B-cells, preferably malignant B-cells are disposed to be BCMA positive, comprising administration of a therapeutically effective amount of an anti-BCMA antibody to said patient. ### Claim 17 A method for the treatment or amelioration of a multiple myeloma (MM) patient whose B-cells, preferably malignant B-cells are BCMA negative, comprising administration of a therapeutically effective amount of an anti-CD20 antibody and/or an anti-CD38 antibody and/or anti-CS1 antibody to said patient. ### Claim 18 (depends on 1) The method of claim 1, wherein said BCMA protein is detectable with Vicky 1 or MAB 193. ### Claim 19 (depends on 2) The method of claim 2, wherein said BCMA protein is detectable with Vicky 1 or MAB 193. ### Claim 20 (depends on 3) The method of claim 3, wherein said BCMA protein is detectable with Vicky 1 or MAB 193. ### Claim 21 (depends on 1) A kit comprising an anti-BCMA antibody and instructions for carrying out the method of claim 1. ### Claim 22 (depends on 2) A kit comprising an anti-BCMA antibody and instructions for carrying out the method of claim 2. ### Claim 23 (depends on 3) A kit comprising an anti-BCMA antibody and instructions for carrying out the method of claim 3.